People

Vibhudutta  Awasthi , Ph.D.

Professor and Sandra K. & David L. Gilliland Chair in Nuclear Pharmacy

Department of Pharmaceutical Sciences

Phone 405-271-6593  x47331
Fax 405-271-7505
Office   CPB 309
Email vibhudutta-awasthi@ouhsc.edu

Research Summary

My laboratory is engaged in multidisciplinary research, from small molecules and peptide synthesis, formulation development, in vitro characterization, radiolabeling with imageable radionuclides to in vivo evaluation of pharmacokinetics and biodistribution in animal models of human diseases. A few of the research projects that involve such an approach are as follows:
  1. GRP receptor targeted EF24 as anticancer agent in pancreatic cancer
  2. Formulation development of liposome-encapsulated hemoglobin and its biologic evaluation as an artificial oxygen carrier in animal models of hemorrhagic shock
  3. Development of CLEFMA, 4-[3,5-bis(2-chlorobenzylidene-4-oxo-piperidine-1-yl)-4-oxo-2-butenoic acid], as an anticancer agent. We are developing nanoparticular delivery agent to deliver this novel drug
  4. Imaging correlates in biomedical research. Our laboratory closely works with the Research Imaging Facility to develop Positron Emission Tomography (PET) and Single Photon Emission Tomography (SPECT) imaging solutions to address pathophysiological and functional issues in research involving animal models.

Education & Experience

Education:
  • Ph.D., Nuclear Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh (India). 1991-1994.
  • M. Pharm., Pharmaceutics, Dr. Hari Singh Gour University (formerly University of Saugor), Saugor, Madhya Pradesh (India).
  • Four-year B. Pharm. degree from Dr. Hari Singh Gour University, Saugor, India. 1984-1988.

Experience:

  • Professor, Dept. of Pharmaceutical Sciences, OU College of Pharmacy, OKC, OK. 2013-present.
  • Associate Professor, Dept. of Pharmaceutical Sciences, OU College of Pharmacy, OKC, OK. 2006-2013.
  • Adjunct Associate Professor, Dept. of Radiation Oncology, OU College of Medicine, OKC, OK. 2010-present.
  • Asst Professor, Radiology Dept., UTHSCSA, TX. 2001-2006.
  • Adjunct Asst Professor of Radiation Oncology, UTHSCSA, TX. 2003-2006.
  • Postdoctoral Res Fellow, Dept. of Physiology, UTHSCSA, TX. 1997-2000.
  • Postdoctoral Res Fellow, Dept. of Radiology, UTHSCSA, TX. 1996-1997.
  • Senior Lecturer, Pharmacy, SBSM Institute of Biomedical Sciences, Dehradun, UP (India). 1995-1996.
  • Asst. Mgr (R&D), Nestor Pharmaceuticals Pvt. Ltd., India. 1994-1995.

Honors & Service

  • Univ. Grants Comm., India-Graduate Aptitude Test in Engineering (GATE) fellowship in M. Pharm. (1988-90).
  • Council for Scientific and Industrial Research (SCIR), India, fellowship in Ph.D. (1992-94).
  • Research Seed Grant from Radiological Society of North America, USA (2003-04).
  • Founder President, Research Fellows Assn, Lucknow, India (1992-93).
  • President, Indo-American Society of Nuclear Medicine, 2011.
  • Study Section member, NIH Small Business: Digestive Sciences and Diagnostics. March 14, 2011.
  • Robert Glenn Rapp Foundation Presidential Professor. May 2013.

Patents

  • Awasthi V, Lagisetty P. Antiproliferative compositions comprising curcumin analogs and methods of producing and using same. US Patent application filed on 06/29/2010.
  • Awasthi V, Lagisetty P. Anionic lipids and lipid nano-structures and methods of producing the same. US Patent application publication # U.S. Patent Number: 8,420,118.

Selected Publications & Presentations

  1. Awasthi V, Watson J, Gali H, Matlock G, McFarland A, Bailey J, Anzellotti A. A dose on demand biomarker generator for automated production of [18F]- and [18F]FDG. Appl Radiat Isot 2014; 89: 167-175.
  2. Yadav V, Sahoo K, Awasthi V. Pre-clinical evaluation of CLEFMA, 4-(3,5-bis(2-chrlorobenzylidene)-4-oxo-piperidine-1-yl)-4-oxo-2-btenoic acid in a mouse model of lung cancer xenograft. J Brit Pharmacol 2013; 170(7): 1436-1448.
  3. Yadav V, Sahoo K, Roberts P, Awasthi V. Pharmacologic suppression of inflammation by a dipheyldiffluoroketone, EF24, in a rat model of fixed-volume hemorrhage improves survival. J Pharmacol Exp Therap 2013; published online before print. DOI: 10.1124/jpet. 113.208009.
  4. Awasthi V, Yadav VR, Goins B, Phillips WT. Modulation of oxidative stability of haemoglobin inside liposome-encapsulated haemoglobin. J Microencapsul 2013; 30(5): 471-478.
  5. Aravindan S, Natarajan M, Herman TS, Awasthi V, Aravindan N. Molecular basis of 'hypoxic' breast cancer cell radio-sensitization: Phytochemicals converge on radiation induced Rel signaling. Radiation Oncology 2013; 9*1): 46.
show more
 

Current Grants Awarded

Current Grants:

  • NIH (NCI) R03 - Pancreatic cancer therapy with GRP receptor-targeted imageable diphenyl diphenyl difluoroketone.
  • NIH (NHLBI) R01 - Biologic evaluation of liposome-encapsulated hemoglobin.

Completed Grants

  • NIH - Positron emission tomography (PET) evaluation of hemorrhagic shock and resuscitation
  • NIH-NHLBI - Biologic evaluation of liposome-encapsulated hemoglobin
  • NIH - SPECT imaging module (S10 equipment grant)
  • Cellphire, Inc. - Evaluation of thrombosomes in a rabbit model